P
Phillip S. Moore
Researcher at Wake Forest Baptist Medical Center
Publications - 9
Citations - 531
Phillip S. Moore is an academic researcher from Wake Forest Baptist Medical Center. The author has contributed to research in topics: Kidney transplantation & Transplantation. The author has an hindex of 8, co-authored 9 publications receiving 508 citations.
Papers
More filters
Journal ArticleDOI
A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation.
Alan C. Farney,William Doares,Jeffrey Rogers,Rajinder Singh,Erica L. Hartmann,Lois J. Hart,Elizabeth E. Ashcraft,Amber Reeves-Daniels,Michael D. Gautreaux,Samy S. Iskandar,Phillip S. Moore,Patricia L. Adams,Robert J. Stratta +12 more
TL;DR: Survition, initial length of stay, and maintenance immunosuppression were similar between alemtuzumab and rATG groups, but biopsy-proven acute rejection (BPAR) episodes occurred in 16 (14%) alem TZU patients compared with 28 (26%) rAT G patients, and alem tzimab was associated with less BPAR.
Journal ArticleDOI
Intermediate-term outcomes with expanded criteria deceased donors in kidney transplantation: a spectrum or specter of quality?
Robert J. Stratta,Michael S. Rohr,Aimee K. Sundberg,Alan C. Farney,Erica L. Hartmann,Phillip S. Moore,Jeffrey Rogers,Samy S. Iskandar,Michael D. Gautreaux,David F. Kiger,William Doares,Teresa K. Anderson,Gloria Hairston,Patricia L. Adams +13 more
TL;DR: By appropriate donor and recipient profiling and the use of management algorithms to project and protect renal function, excellent intermediate-term outcomes can be achieved with ECD kidneys transplants that are comparable to SCD kidney transplants.
Journal ArticleDOI
Influence of pulsatile perfusion preservation on outcomes in kidney transplantation from expanded criteria donors.
Robert J. Stratta,Phillip S. Moore,Alan C. Farney,Jeffrey Rogers,Erica L. Hartmann,Amber Reeves-Daniel,Michael D. Gautreaux,Samy S. Iskandar,Patricia L. Adams +8 more
TL;DR: Despite longer cold ischemia times, recipients of ECD kidneys managed with PPP had similar survival and functional outcomes, but experienced a marked reduction in the rate of delayed graft function.
Journal ArticleDOI
A randomized trial of alemtuzumab vs. anti-thymocyte globulin induction in renal and pancreas transplantation.
Alan C. Farney,Aimee K. Sundberg,Phillip S. Moore,Erica L. Hartmann,Jeffrey Rogers,William Doares,Anne Jarrett,Patricia L. Adams,Robert J. Stratta +8 more
TL;DR: In the short term after kidney and pancreas transplantation, alemtuzumab and rATG induction therapies are similarly safe and effective.
Journal ArticleDOI
Dual kidney transplantation: a case-control comparison with single kidney transplantation from standard and expanded criteria donors.
Phillip S. Moore,Alan C. Farney,Aimee K. Sundberg,Michael S. Rohr,Erica L. Hartmann,Samy S. Iskandar,Michael D. Gautreaux,Jeffrey Rogers,William Doares,Teresa K. Anderson,Patricia L. Adams,Robert J. Stratta +11 more
TL;DR: In this article, a case-matched cohort analysis of dual kidney transplantation from expanded criteria donors (ECDs) compared to single kidney transplant (SKT) from concurrent ECDs and standard criteria donors was performed.